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Topical formulationsRecently we described the pH dependence of activity for a family of cationic antimicrobial peptides (CAMPs)
selected from a combinatorial library. In the current work we report on the effects of toxic ions (Cu2+, Zn2+,
and F−) and the chelator EDTA on the activity proﬁles of one member of this family, the 12-residue cationic an-
timicrobial peptide *ARVA, against a panel of microorganisms. All four ions exhibited either synergy or additivity
with *ARVA for all organisms tested with the exception of *ARVA combined with NaF against Candida albicans
which exhibited indifference. CuCl2 and ZnCl2 exhibited synergy with *ARVA against both the Gram negative
Pseudomonas aeruginosa and the Gram positive Staphylococcus aureus as well as strong additivity against
Escherichia coli at submillimolar concentrations. The chelator EDTA was synergistic with *ARVA against the two
Gram negative organisms but showed only simple additivity with S. aureus and C. albicans despite their much
lowerMICs with EDTA. This effect may be related to the known differences in the divalent ion binding properties
of the Gramnegative LPS layer as compared to the peptidoglycan layer of the Grampositive organism. Unlike the
other ions, NaF showed only additivity or indifference when combined with *ARVA and required much higher
concentrations for activity. The yeast C. albicans did not show synergy or strong additivity with any of the inhib-
itory compounds tested. The effects of toxic ions and chelators observed here have important implications for ap-
plications using CAMPs and for the design of novel formulations involving CAMPs. This article is part of a Special
Issue entitled: Interfacially Active Peptides and Proteins. Guest Editors: William C. Wimley and Kalina Hristova.
© 2014 Elsevier B.V. All rights reserved.1. Introduction
Antibiotic resistance continues to be a signiﬁcant problem with an
increasing number of hospitalizations and deaths attributed to resistant
organisms each year [1,2]. Developing new antibiotics and new formu-
lations is essential to combating this threat. Cationic antimicrobial pep-
tides (CAMPs) are potential drug candidates, having broad spectrum
activity, high potency, and showing little tendency for microbial
resistance [3–5].
CAMPs are a central component of the innate immune system in or-
ganisms ranging from invertebrates to plants to humans [6,7]. Most
CAMPs share common characteristics such as low molecular weight
and an amphipathic sequence containing both hydrophobic and cation-
ic amino acids [3]. Most CAMPs or synthetic mimics appear to work by
increasing the permeability of the cytoplasmic membranes of targeted
organisms, although they may have additional intracellular targets [5,
8–10]. The rarity of resistance to CAMPs is often ascribed to the lack ofconcentrations; MICs, peptide
microbial peptides
lly Active Peptides and Proteins.
).a distinct macromolecular target and to the large energetic cost in
reorganizing the membrane surface of an organism [4,11].
The CAMP peptide family that contains *ARVA, designed to have
β-sheet secondary structure inmembranes,was selected froma combi-
natorial library [12] using lysis of a simplemodelmembrane as a screen.
Surprisingly, the peptides were found to have broad spectrum antimi-
crobial activity [13] despite the general nature of the screen. The prima-
ry structure of a promisingmember of this family, the peptide *ARVA, is
described below. The peptides are named using the nomenclature
adopted previously [13,14] to describe members of this family which
contain a common 9-residue core motif with or without the presence
of cationic terminal tripeptide cassettes. The asterisks designate the
presence of a RRG- or -GRR terminal cassette and the one letter codes
represent the amino acids found at each of the four varied positions
(O) within the 9-residue core sequence, WOLOLOLOY. The peptides
synthesized varied between 9 and 15 amino acids in length. The peptide
used in this work, designated *ARVA, is a 12 amino acid peptide
(RRGWALRLVLAY-NH2) containing an N-terminal Arg–Arg–Gly
cassette and containing A, R, V, and A respectively at the four varied
(O) positions. The peptide is amidated at the C-terminus.
The initial step for CAMPs involves a binding event in which the
positively charged peptides interact with the anionic plasma mem-
branes of microorganisms [4,5]. In our previous study [14], we found
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crobial cell wall or lipopolysaccharide layers [15–17] were also critical.
Subsequent to binding of the plasma membrane, the amphipathic
CAMPs interact with the nonpolar constituents of membrane lipids [7]
and cause cell death due to membrane disruption via interfacial activity
or a related mechanism rather than by pore formation although other
mechanisms have also been proposed [11].
Due to the common difﬁculties associated with peptide drugs (e.g.
solubility, cost, degradation), the most likely applications for CAMPs
will be in topical or surface sterilization applications or to limit hospital-
acquired infections [3,18]. Diabetic ulcers and other skin infections such
as thrush, as well as infections related to cystic ﬁbrosis have been the
subject of several clinical trials [19] and new candidates have recently
appeared [20].
Since it seems likely that CAMPs will often be used in situations
where the environment can be varied such as in ointments, mouth-
washes, and lavages, it is important to thoroughly understand the
effects of environmental factors on the efﬁciency of CAMPs in directly
killing bacteria [18,20]. A number of studies have looked at the effects
of pH or salt concentration on the ability of CAMPs to kill microorgan-
isms [21,22]. For example, it is well known that higher salt concentra-
tions often interfere with CAMP activity and may be clinically relevant
[23–25]. In our previous work [14] we investigated the effect of a
wide range of pH and ionic strength values on CAMP activity.
Metals and toxic ions have been used in medicine and agriculture
since antiquity [26–28] and new applications such as in combating
bioﬁlms and improved wound care continue to be explored [29–31].
Heavy metals in particular have a long history of use in medicine and
have recently garnered renewed interest in the form of nanoparticle
andmodiﬁed surface technologies [32,33]. Zinc and copper are essential
micronutrients for most cells but are toxic to prokaryotic cells at
submillimolar concentrations [34–36] and to eukaryotic cells at higher
concentrations or in ion transport diseases [37,38]. More than 30 copper
proteins have been identiﬁed in higher organisms, but many fewer are
found in bacteria and some bacteria appear to have no copper proteins.
As a consequence, bacteria often do not contain ion transporters capable
of importing copper and instead rely on pumps to export excess copper
and, in some cases, binding proteins to maintain copper homeostasis
[34,36]. Traditionally the toxic effects of copper have been attributed
to Fenton type reactions creating reactive oxygen species such as H2O2
in the cytoplasm (oxidative stress) or to depletion of cellular sulfhydryl
species [36] butmore recent evidence points toward disruption of iron–
sulfur proteins by displacement of iron by copper [34,36].
Zinc, on the other hand, is found in a greater number of proteins in
both prokaryotes and eukaryotes and most bacteria do have trans-
porters that import zinc as needed. The free concentrations for both
metals, however, are maintained at extremely low concentrations in
bacterial cells [34,36,38]. Zinc is often used in oral care products [39,
40] and has been found to have a number of bacteriostatic effects at
submillimolar concentrations against a variety of aerobic and anaerobic
organisms. Zinc enhances the membrane permeability of protons and
thus interferes with F-ATPase activity and in addition is an inhibitor
of glycolytic enzymes [39,41]. Disruption of the proton gradient and gly-
colysis results in a reduction of the acid secretion often implicated in
cariogenesis. Zinc toxicity for bacteria such as S. pneumoniae, on the
other hand, appears to be related to competition with import of other
essential cation species such as Mn(II) [35]. While some AMPs, such as
the anionic dermcidin derived peptides found in human sweat [42], or
the histidine containing demegen from saliva [43] require zinc for
activity, this is not the case for the cationic *ARVA which contains no
histidines.
Toxic or bacteriostatic anions such as EDTA and NaF are commonly
used in the food industry [44], in oral health applications [28,39,45,
46], and in the medical technology industry [31,47,48], often in
prophylactic formulations. In many organisms, ﬂuoride is toxic only at
relatively high concentrations. One of the earliest reports (in 1903),for example, found that Saccharomyces cerevisiae was killed by 250
mMNaF (~4500 ppm) [28]. By comparison, drinkingwater is oftenﬂuo-
ridated to a level of 1 ppm while most commercial toothpastes contain
~1000 ppm ﬂuoride. Fluoride acts through a variety of effects including
enzyme toxicity, mimicry of phosphate by metal–ﬂuoride complexes,
and strong inhibition of F-ATPases via enhanced proton permeability
ofmembranes in the formofHF [28,39,49]. The effects on some oral bac-
terial species can occur in the micromolar to low millimolar (~1–200
ppm) concentration range, depending on pH, although anticariogenic
effects are also related strongly to effects on the remineralization of
tooth enamel [46,50].
Development of resistance to single drug treatments bymicroorgan-
isms and cancerous cells is commonly encountered. To counter this, the
use of multiple drug treatments has been adopted to improve the clini-
cal outcomes for a variety of infective organisms as well as in chemo-
therapy [51–54]. Here we extend our work on environmental effects
on antimicrobial peptide activity by testing for synergy between toxic
ions and the synthetic CAMP *ARVA. We examined the effects of two
toxic cations (Cu2+, Zn2+) and two toxic anions (EDTA, F−) when
used in combination with *ARVA.
2. Materials and methods
2.1. Bacterial cultures
Strains of Escherichia coli (ATCC 25922), Staphylococcus aureus
(ATCC 25923), Pseudomonas aeruginosa (ATCC 27853) and Candida
albicans (ATCC 90028) were obtained from the American Type Culture
Collection (Rockville, MD). The bacterial and yeast cultures were main-
tained in Trypticase soy broth (TSB) and YPD broth (Difco Laboratories,
Detroit, Mich.) respectively. Overnight cultures of bacteria were grown
in 50 mL tubes shaken at 220 rpm at 37 °C. Overnight cultures of
yeast were grown at 30 °C.
2.2. Antimicrobial activity assays
Most buffer solutions and microbial suspensions were prepared in a
liquid test medium (LTM) background containing 1% growth broth in
0.1 M MOPS at pH 7. CuCl2, ZnCl2, and *ARVA solutions were prepared
in 0.025% acetic acid while NaF used LTM made with PBS. MOPS was
used rather than phosphate in these studies as divalent ionswill precip-
itate in the presence of phosphate. E. coli, P. aeruginosa, S. aureus and
C. albicanswere grown tomid-logarithmic phase and diluted to 104 col-
ony forming units (CFU)/mL with minimal liquid test medium (LTM).
Exposure time in minimal media was limited to avoid depleting nutri-
ents prior to incubation. EDTA:*ARVA combinations in particular could
give very low MSC values when cells were left for more than an hour
in minimal media. We have shown that increasing the experimental
cell counts up to 105/mL uniformly increases MSC values by several-
fold, but does not affect the functional dependence of MSC measure-
ments [13]. Assays were performed in sterile Costar 96-well ﬂat bottom
plates (Corning, Lowell, MA).
Preliminary MSC assays had a ﬁnal assay volume of 200 μL contain-
ing 100 μL of cell suspension (2× 104 CFU/mL inminimal LTM) added to
100 μL of 0.025% acetic acid containing various concentrations of toxic
or inhibitory ions (CuCl2, ZnCl2, EDTA, NaF) or the peptide *ARVA that
had been serially diluted (2-fold) across each row. Initial concentrations
appropriate for eachmicrobe being testedwere added to theﬁrstwell of
each rowbefore dilution. Typical starting concentrationswere 10 μMfor
*ARVA, 500 mM for NaF, and 10–50 mM for CuCl2, ZnCl2, and EDTA.
Rows were set up in pairs, with and without treatment, to control
for bacterial growth in LTM. The well plates were then incubated at
37 °C for 30 min to allow killing to occur. Variation of the initial incu-
bation time between 15min and 1 h had no signiﬁcant effect. Follow-
ing this initial incubation step, 100 μL of 3× concentrated growth
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were allowed to recover by overnight incubation at 37 °C.
Synergy assays (J. He and W. Wimley, personal communication,
manuscript describing new synergy assay in preparation) were pre-
pared in a similar fashion except that the reagents were added as
“triplets” to sets of three columns and 2-fold serial dilutions were
made down the column (Fig. 1). Synergy assays had aﬁnal assay volume
of 200 μL containing 100 μL of cell suspension (2 × 104 cells/mL in min-
imal LTM) and 100 μL of containing various concentrations of toxic or
inhibitory ions (CuCl2, ZnCl2, EDTA, NaF) and/or *ARVA in 0.025% acetic
acid. Plates were prepared in the following manner. First, 100 μL of
0.025% acetic acid was added to all wells. The peptides and ions to be
tested were then added to the top well in each column such that the
total volume was 200 μL with additional 0.025% acetic acid added as
necessary to reach the ﬁnal volume. In each set of three columns, re-
agent Awas added by itself at somemultiple of MSC to the ﬁrst column,
reagent B was added similarly to the second column, and in the third
column, both reagents A and B were added but at half the respective
concentrations used in the ﬁrst two columns. Typically, four replicates
of such triplets were prepared in a single 96-well plate. Dilutions were
then made down the columns by serially transferring 100 μL resulting
in a ﬁnal volume of 100 μL. A volume of 100 μL of LTM (0.1 M MOPS)
containing bacterial suspensions (104 CFU/mL) was then added to
each well and the plates incubated at 37 °C for 30 min followed by
addition of 100 μL of 3× TSB growth media and overnight incubation
at 37 °C.
Cell survivalwas evaluated by visual inspection aswell asmeasuring
optical density at 600 nm.Wells were either opaque (OD N 0.5) indicat-
ing stationary phase growth or they were transparent (OD b 0.02) indi-
cating no growth (see Fig. 1). Very few wells had intermediate growth,
but those that did were assigned a value of 0.5 columns killed. Aliquots
from wells with no apparent growth were spread on nutrient agar
plates to verify sterility and count colonies if present. In most cases
there were few if any CFU in wells containing *ARVA compared to
108 CFU/μL in the opaquewells. EDTAwas found to bemostly inhibitory
(bacteriostatic) and wells plated for EDTA in the absence of *ARVA typ-
ically contained several thousand colonies, consistent with the number
in the initial inoculum. CuCl2 and ZnCl2 sterilized at higher concentra-
tions but often contained hundreds of colonies at lower concentrations
in the absence of *ARVA.Fig. 1. Typical 96-well data acquired in these experiments. Data shown are for *ARVA in
combination with CuCl2 against E. coli. The 12 columns are prepared in sets of 3 columns.
Columns 1, 4, 7, and 10 contain only CuCl2 (Cu2+ inﬁgure) at 4×MSC, columns 2, 5, 8, and
11 contain only the peptide *ARVA (P in ﬁgure) at 4×MSC and columns 3, 6, 9, 12 are the
synergy columns (Syn in ﬁgure) containing both compounds at 2× MSC. The plates are
sequentially diluted (2-fold) down each of the 8 rows of the plate. Opaque wells are
overgrown with bacteria while clear wells indicate sterilization at that concentration.2.3. Data analysis
For most experiments there were a number of sterile wells starting
from the highest concentration of peptide. The lowest concentration
of peptide that prevented cell growth is the minimum sterilizing con-
centration (MSC). For EDTA, the value should be considered a minimal
inhibitory concentration (MIC). The MSC values were calculated by
converting number of wells killed into a concentration value using the
relation MSC= C ∗ D(n− 1) where C is the initial peptide concentration,
D is the dilution factor for that experiment, and n is the number of wells
killed. ReportedMSC values are the average of 12–21data points. Unless
indicated otherwise, all error bars are ±1 standard error.
Synergy data were analyzed using the following [55,56] deﬁnitions:
FICA = MSCCa / MSCA and FICB = MSCCb / MSCB
where FICA is the fractional inhibitory concentration for compound A
deﬁned as the ratio of the MSC for compound A when combined with
compound B (MSCCa) divided by theMSC of compound A alone (MSCA)
and similarly for FICB. The MSCC values were determined from the third
(combined) column in each triplet as the average of 12–21 separate de-
terminations as described above while the values for MSCA and MSCB
were similarly determined from columns one and two of each triplet.
The average MSC values were then used to calculate the values of FICA
and FICB for each set of experiments. FICA and FICB are not constants
as they can vary as the ratios of compoundsA and B are varied. The value
of the overall FIC value used to determine synergy or additivity is a
constant designated FICC and is calculated simply as FICC= FICA+ FICB.
The following values of FICC are used to assign interactions: a value b0.5
indicates synergy, a value between 0.5 and 2.0 indicates additivity, a
value between 2.0 and 4.0 indifference, and a value N4.0 antagonism
[55,56]. Standard errors for FIC values were estimated from the family
of FICs calculated individually using MSC data grouped in the same
96-well plates.
3. Results
3.1. Synergy assay
Synergy data were collected for the CAMP *ARVA against a panel of
microorganisms as described in the Materials and methods section. In
Fig. 1, the results for a typical synergy assay (in this case for *ARVA/
CuCl2 against E. coli) are displayed. The 12 columns are arranged in
sets of three (triplets) in the following manner. In row A, columns 1,
4, 7, and 10 contain CuCl2 at 4× MSC, columns 2, 5, 8, and 11 contain
the peptide *ARVA at 4× MSC, and columns 3, 6, 9, and 12 contain
both compounds at 2× MSC. Each row is diluted serially by 2-fold dilu-
tions such that the concentrations in row B are 1/2 of row A and so on.
Following the addition of bacteria, the plates are incubated for
30 min, growth media added and the plates allowed to recover over-
night at 37 °C (see the Materials and methods section). Each column
contains clear wells indicating complete sterilization during the incuba-
tion period with no subsequent growth overnight. The columns con-
taining CuCl2 alone were completely sterilized down to a MSC value of
~500 μM (3–4 wells killed) while those containing *ARVA had an MSC
of ~2.2 μM (3 wells killed). When combined at 2× MSC (column 3),
killing was observed for 4 wells which corresponds to ~250 μM for
CuCl2 and 0.25 μM for *ARVA (see Table 1).
3.2. Effects of CuCl2 and ZnCl2
The results of synergy assays performed with all four microorgan-
isms using *ARVA paired with CuCl2 (Table 1) and ZnCl2 (Supplementa-
ry Table S2) are given below. In each table, the number of separate
determinations (n) is given along with the MSC concentrations and
FIC values for each compound and combination. The tables are arranged
Table 1
Synergy data for *ARVA with CuCl2.
Organism MSC ± standard error (μM)
n [*ARVA]C [*ARVA]A FICA [CuCl2]C [CuCl2]B FICB FICC Interpretation
Gram negative
P. aeruginosa 20 0.11 ± 0.02 2.9 ± 0.2 0.04 ± 0.02 136 ± 24 442 ± 120 0.31 ± 0.15 0.35 ± 0.15 Synergistic
E. coli 17 0.25 ± 0.07 2.2 ± 0.2 0.11 ± 0.04 246 ± 72 506 ± 110 0.49 ± 0.14 0.60 ± 0.16 Additive
Gram positive
S. aureus 13 0.19 ± 0.07 3.9 ± 0.3 0.05 ± 0.02 930 ± 333 4500 ± 490 0.21 ± 0.08 0.26 ± 0.09 Synergistic
Yeast
C. albicans 12 0.67 ± 0.07 1.8 ± 0.06 0.37 ± 0.04 3400 ± 340 4200 ± 350 0.81 ± 0.13 1.18 ± 0.17 Additive
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is listed ﬁrst followed by the MSC value for that compound alone
(subscript A for *ARVA and subscript B for the toxic ion) and by the in-
dividual FIC values for each compound. At the far right of each table, the
combined FIC value (FICC) and interpretation are given.
The FICC values (±1 standard error) for each toxic ion paired with
*ARVA against the panel of microorganisms are plotted in Fig. 2 while
the individual FICA and FICB values for each combination are plotted in
Fig. 3. Two sets of synergy assays conducted with varied starting ratios
of *ARVA:CuCl2 for E. coli are given in Supplementary Table S3 and
plotted in Fig. 3 (open circles).
When *ARVA and CuCl2 are used in combination, there are synergis-
tic or strongly additive effects for all three bacteria tested. The concen-
tration of *ARVA needed for complete sterilization in the presence of
submillimolar concentrations of CuCl2 (100–900 μM depending onFig. 2. The FICC values for *ARVA in combination with each ion are plotted. Panels A–D show da
plotted a scale from 0 to 1.2 except for C. albicans which is plotted from 0 to 3.5.microbe) is decreased by a factor of 9–25 fold down to submicromolar
concentrations of *ARVA in the 100–250 nM range (Table 1). The
resulting FICA values thus fall in the range from 0.04 to 0.11. The effect
on theMSC of CuCl2 is less pronounced. The two Gram negative species
are already fairly sensitive to CuCl2 withMSCs in the 400–500 μM range
but in the presence of *ARVA they decrease roughly 2–3 fold. S. aureus,
on the other hand, requires 4.5 mM CuCl2 for sterilization, but in the
presence of *ARVA this is reduced about 5-fold to less than 1 mM.
For C. albicans, the effect is additive but the resulting FICA value is
about 0.37 while the FICB value is 0.81. The individual FIC values are
plotted in Fig. 3 (ﬁlled circles) as FICB versus FICA to highlight the rela-
tive effects on the MSC of each compound when used in combination.
Adding the two values (x and y coordinates) results in the FICC values
which are given at the far right of Table 1 and also plotted in Fig. 2
(panels A through D). The FICC values for P. aeruginosa (Fig. 2B) andta against E. coli (A), P. aeruginosa (B), S. aureus (C), and C. albicans (D). The FICC values are
Fig. 3. Values for FICIon are plotted versus FIC*ARVA for each of the four toxic ions. CuCl2 data are plotted as circles, EDTA as triangles, NaF as squares, and ZnCl2 as diamonds. Datawith ﬁlled
symbols are fromone set of peptide:ion ratios (Tables 1, 2, 4, and 5)while open symbols are data using altered ratios of peptide compared to the toxic ion (Table S3). Panels A–D showdata
collected against E. coli (A), P. aeruginosa (B), S. aureus (C), and C. albicans (D).
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*ARVA and CuCl2 while that for E. coli (Fig. 2A) is 0.6 which indicates
strong additivity — in contrast to the C. albicans (Fig. 2D) value of 1.18
suggesting simple additivity. Given additivity or synergy, however, the
values of FICA and FICB are a function of the concentration ratios chosen
for the two species. To test this idea,we ran two additional sets of assays
using E. coli with the *ARVA:CuCl2 ratios varied (top of Table S3) and
plotted these as open circles in Fig. 3A. By increasing the concentration
of *ARVAwhile decreasing the concentration of CuCl2 in 2-fold steps,we
were able to decrease the FICB from about 0.5 down to 0.14 (for CuCl2)
while increasing the FICA from 0.11 to 0.33 for *ARVA. The FICC however
changes much less than either of the individual FIC values, verifying the
additive effect of the two compounds. Two of the values of FICC for
*ARVA with CuCl2 were nearly identical (~0.6) indicating strong addi-
tivity, but the third value of FICC of 0.47 suggests synergy, although all
three values are consistent within standard error.
The data for synergy assays using *ARVA in combination with ZnCl2
are given in Table S2 and FIC values plotted as before in Figs. 2 and 3
(diamond symbols). The data show a very similar pattern to that for
CuCl2 with all three bacteria showing a strong effect for ZnCl2 while
C. albicans exhibits simple additivity. Again E. coli (Fig. 2A) exhibits
strong additivity while the FICC values for P. aeruginosa (Fig. 2B) and
S. aureus (Fig. 2C) indicate synergy. The decrease in MSC for *ARVA is
very similar for all four microbes in the presence of ZnCl2 with all FICA
values falling between 0.17 and 0.31 indicating a 3–6 fold decrease in
the concentration of *ARVA needed for killing. In addition, all four
MSC values for *ARVA were similar, falling in the 400–800 nM range.
The concentrations of ZnCl2 required were 2–5 fold lower than forCuCl2 for both ZnCl2 alone (200–1400 μM) and in the presence of
*ARVA (50–170 μM) for the three bacteria but were more similar for
C. albicans. The same pattern, with S. aureus less sensitive to the metal
chloride in the absence of *ARVA but showing a much smaller FICB
than the Gram negative organisms, was observed with ZnCl2.
3.3. Effects of EDTA
The synergy assay data for EDTA in combination with ARVA is given
in Table S4 and plotted in Figs. 2 and 3 (closed triangles). In addition, ad-
ditional synergy data using varied ratios of *ARVA:EDTA were collected
for both E. coli and S. aureus and are summarized in Table S3 and plotted
in Fig. 3 as open triangles.
FICC values for both Gram negative organisms show synergy while
that for S. aureus and C. albicans show simple additivity. However, the
measured FICA values for all microorganisms tested are similar,
exhibiting 5–10 fold decreases of MSC down to 250–500 nM *ARVA.
The Gram negative organisms show a large effect on FICB as well with
the MIC for EDTA decreasing 5-fold down to ~1 mM. At the original
*ARVA:EDTA ratio (Table S4) the MSC for *ARVA decreased about
10-fold (FICA = 0.09) against E. coli, but at two different *ARVA:
EDTA ratios (Table S3), the measured FICA value (*ARVA) increased
2-fold to ~0.20 (MSC ~ 500 nM) while the measured FICB value
(EDTA) fell to as low as 0.05 indicating that the MIC can decrease by a
factor of 20 down to ~200 μMEDTA in thepresence of increased [*ARVA].
Interestingly, the MICs for EDTA for both S. aureus and C. albicans
(300–600 μM) are already much lower than for the Gram negative or-
ganisms (4–5 mM) and decrease very little in the presence of *ARVA.
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FICB value for EDTA falls as low as 0.45, indicating that the [EDTA] nec-
essary for killing in the presence of *ARVA can decrease from ~700 μM
down to ~300 μM. The FICC decreases as well to 0.83 but still falls in
the additive range.
3.4. Effects of NaF
Synergy data for NaF combined with *ARVA are given in Table S5
and plotted in Figs. 2 and 3 (square symbols). Unlike the other ions
tested, no combination of NaF with *ARVA resulted in synergy or
strong additivity for any of the organisms targeted. All three bacteri-
al species did exhibit simple additivity however, resulting in FICA
and FICB values in the range from 0.35 to 0.71 and FICC values near
1.0. As a consequence, the presence of ~50mMNaF (~1000 ppm) re-
duced the MSC for *ARVA to near 1 μM. The effect was most substan-
tial for S. aureus where the MSC decreased nearly 3-fold to ~1.4 μM
*ARVA in the presence of ~70 mM NaF. The MSC values for NaF
with the two Gram negative organisms decreased the most (~2-
fold; FICB ~ 0.5) down to ~50 mM NaF.
The results for *ARVA:NaF against C. albicans were not promising
with the MSC for NaF only decreasing by 35% in the presence of
*ARVA, and the presence of ~200 mM NaF actually increasing the con-
centration of *ARVA required by nearly 3-fold. The resulting FICC value
for *ARVA:NaF is 3.35 indicating that at these concentrations, the two
compounds are acting independently (borderline antagonism) instead
of additively due mainly to the strong effects on the MSC of *ARVA
and thus FICA. Note that the scale of the y-axis in Fig. 2D is expanded
to allow this value to be plotted and that the values for NaF with
*ARVA are not plotted in Fig. 3D (see Table S5 instead).
4. Discussion
The search for new compounds and improved formulations to com-
bat microbial infections is necessarily a continuous process in order to
stay one step aheadof the acquisition of resistance by pathogenicmicro-
organisms [18]. Cationic AMPs (CAMPs) have been studied extensively
due to advantages such as broad speciﬁcity and lack of resistance, al-
though these advantages are tempered by disadvantages such as cost,
susceptibility to degradation, and possible toxicity common to peptide
drugs [3,4]. Many anticipated uses of CAMPs are in areas such as topical
or surface applications [3,6]. In fact, most clinical trials to date involve
the treatment of skin infection or the use of CAMPs in preventing sur-
face colonization and bioﬁlms [18,20]. Such applications allow a wider
variety of environmental conditions than is possible with systemic ad-
ministration. The use of toxicmetals and ions to combatmicrobial infec-
tions has received renewed interest recently in the areas of surface
modiﬁcation, nanoparticle applications, and combating bioﬁlms, some-
times in combination with CAMPs [29,30,32,33,39,57]. A fuller under-
standing of the effects and interactions of environmental factors such
as pH, ionic strength, speciﬁc ions, and surface properties on CAMP ac-
tivity will facilitate the development of new applications of CAMPs
and new formulations as potential drug therapies [14,18,20].
Combination therapies are awell established therapymethodwhich
often improve clinical outcomes andmay lower the chances of develop-
ing resistance although the acquisition of multidrug resistance is an in-
creasingproblem [51,53,58–62]. Traditional target based drug discovery
has had limited success in the development of new targets [63]. The
microbial membrane represents a more diffuse target which does not
involve the speciﬁc molecular recognition found with most other
drug–target interactions that actually facilitate the development of re-
sistance [4]. The membrane thus represents an underexploited target
[64] and CAMPs or their mimics [8,9] are ideally suited to this purpose.
Combination therapies can work well as long as there are no unfavor-
able or antagonistic interactions between the drugs that limit the effec-
tiveness of one or both in the presence of the other [51,54]. If the twodrugs show additivity or synergy, additional advantages accrue apart
from those related to preventing development of resistance [59]. For ex-
ample, if additivity or synergy allows lower doses of both drugs to be
used, there are cost savings as well as the possibility of fewer side ef-
fects. In addition, if one compound is much cheaper than the other, as
with *ARVA (or any peptide drug), then the relative ratios of the two
compounds can be adjusted accordingly (see Table S3) to achieve the
maximum therapeutic effect at the lowest cost. Measuring and charac-
terizing additivity and synergy have a long and intricate history
[51–54,58,65–67]. Here we have employed modiﬁed Loewe deﬁnitions
of synergy, additivity, indifference, and antagonism [55,56] and have
used a simple and direct assay to measure the efﬁciencies of microbial
killing by individual and combined treatments involving toxic ions
and the CAMP *ARVA. The results obtained here monitored killing fol-
lowing a brief incubation in minimal media, such asmight occur imme-
diately after topical application using a lavage solution. In future work,
we plan to extend these studies to rich media and using a physiological
solution such as saliva or blood plasma.
An advantage of the assay employed in these studies is that it is
straight forward to obtain a large number of repetitions, and that alter-
nate concentration ratios can be readily compared. In this study, we
chose to analyze the FICA and FICB values separately (Fig. 3, Tables 1,
S2–S5) and showed that by varying the *ARVA:ion concentration ratios
(Table S3) we could tailor individual improvements in MSC values and
thus the FICA and FICB values for each species.
A signiﬁcant result of this work is that all three bacterial species,
both Gram positive and Gram negative, showed either synergistic or
strongly additive effects with the divalent ions Zn2+ or Cu2+ used in
combination with *ARVA. The results for CuCl2 (Table 1) indicated that
the three bacterial species exhibited 9 to 25 fold improvements in the
[*ARVA] required for sterilization (~100–250 nM). Although E. coli did
not exhibit synergy at the original *ARVA:CuCl2 concentration ratios
(Table 1), at some ratios (Table S3), synergy was observed. This high-
lights the importance of varying the concentration ratios in such studies
and in our view suggests that the advantages of additivity may some-
times be overlooked. In this case, though E. coli did not show synergy
in most cases, sterilization was still achieved at 250 nM *ARVA in the
presence of 250 μM CuCl2.
The Gram positive S. aureus exhibited a stronger effect on both FICA
for Cu2+ (ﬁlled circles, Fig. 3) and Zn2+ (diamonds, Fig. 3) and FICC
(Fig. 2), particularly when compared to E. coli (FICC = 0.26 vs. 0.60 for
CuCl2, see also Tables 1 and S2). These differences could reﬂect the dif-
ferent types of metal binding sites found on the outer PG layer of
S. aureus compared to the outer LPS layer of the Gram negative organ-
isms [68–71] or alternately could simply reﬂect species or strain speciﬁc
differences in metal homeostasis factors such as ion pumps and metal
binding proteins (chaperonins) between the organisms [37,72]. Most
eukaryotic organisms are less sensitive to the effects of toxic ions and
can tolerate higher concentrations of such ions [28,37]. Since most mi-
crobes can readily develop resistance to heavy metals [72] the use of
combination therapy can act to limit such resistance. At the same
time, additivity or synergy can allow the use of lower concentrations
of toxic ions, thus limiting potential side effects. As described above,
E. coli showed complete sterilization in the presence of very low concen-
trations of both CuCl2 and *ARVA (Table 1). With alternate ratios of
*ARVA:CuCl2, however, we observed sterilization at a [CuCl2] as low as
60 μM in the presence of 940 nM *ARVA (Table S3). Thus one could
choose to optimize the [*ARVA] to control costs, or alternately, could
choose to lower the [CuCl2] to limit ion toxicity. The results for ZnCl2
(Table S2) were also encouraging in that all four organisms were killed
by *ARVA in the 500 nM range with the three bacterial species only re-
quiring ~50–150 μMZnCl2 to achieve this result. The yeast C. albicans, by
contrast, has anMSC for ZnCl2 as well as for CuCl2 in the 3–4 mM range
(see Tables 1 and S2).
In addition to synergy with divalent ions, we observed that both
Gram negative species show strong synergy with EDTA paired with
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(Fig. 2, Table S4). Relying uncritically on deﬁnitions such as synergy
and additivity, however, can result inmissing potentially signiﬁcant im-
provements in activity. For example, we observed that while the effect
for S. aureus was only additive, the [EDTA] needed was ~600 μM com-
pared to about twice that for the two Gram negative organisms and
that the improvement to the MSC of *ARVA (FICA) was nearly identical
for all three bacteria. In addition by varying the *ARVA:EDTA ratio (see
Table S3), we could observe effects as low as 200–300 μM EDTA for all
three organisms with FICA values between 0.2 and 0.4, thus still
allowing substantially less of the comparatively expensive *ARVA to
be used.
Gram negative organisms contain both an outer lipopolysaccharide
(LPS) layer and a thin proteoglycan (PG) layer external to the plasma
membrane while Gram positive organisms have only a very thick
outer PG layer [73]. Both cell wall outer layers contain charged mole-
cules that bind metal ions and strongly inﬂuence CAMP binding [14].
The thick PG layers of most Gram positive bacteria give them a large ca-
pacity to bindmetal ions [71]. They can do so using both the anionic car-
boxyl groups of their PG layer as well as the anionic phosphoryl groups
of their many wall and membrane bound teichoic acids [74]. The bind-
ing strengths, however, are often somewhat lower for Grampositive or-
ganisms due to the involvement of carboxyl ligands [68,71,75]
compared to the stronger metal binding by Gram negative organisms
using mostly phosphate groups of their LPS layer as ligands [69,75].
Such differences in binding capacity and binding afﬁnity may be related
to the different concentration regimes we observed in these studies
(Tables S3 and S4) for EDTA toxicity between the Gram positive
S. aureus and the Gram negative E. coli and P. aeruginosa.
The mechanism for toxicity for EDTA and other similar molecules is
most likely related to their primary activity which is metal chelation. By
starving growing bacteria of divalent metals such as Ca2+ and Mg2+,
and micronutrients such as Zn2+, Cu2+, and Mn2+, EDTA can act in a
bacteriostatic fashion to prevent bacterial growth. In addition, EDTA
can also remove Ca2+, and Mg2+ from their binding sites in bacterial
cell walls, which function to both store metals for future use and to
crosslink and strengthen bacterial cell walls [73,76,77]. Indeed, EDTA
in combination with amine buffers has long been known to have toxic
effects on bacteria [78]. More recently, EDTA has been employed to
limit bioﬁlms [30], to prevent infections and sterilize catheters [47,48],
and in combinations with CAMPs or other antimicrobials [23,79,80].
In general, for compounds exhibiting simple additivity, no unique
mechanism of toxicity need be invoked. For compounds exhibiting
strong additivity or synergy, however, it is reasonable to infer that an
additional interaction between the two compounds or an additional
mechanism for toxicity must exist. The reason for synergy between
the toxic metals (Zn2+, Cu2+) and *ARVA is unknown but may be relat-
ed to the ability of the antimicrobial peptide to increase the permeabil-
ity of themembranes to the small metal ions. An additional mechanism
which can explain enhanced activity and synergy between EDTA and
cationic compounds such as *ARVA is that upon removal of divalent
metal ions from the bacterial cell walls, the cell walls become much
more anionic and thus attract the cationicmoleculesmuchmore strong-
ly. We recently highlighted the importance of charges on bacterial cell
walls for CAMP action including the ability of high pH to increase nega-
tive charge on S. aureus cell walls, and the potential role ofmodiﬁcations
that neutralize charge on cell walls in infectivity by pathogenic
organisms [14].
In these studies, NaF did not show synergy or strong additivity with
*ARVA (Table S5) but did show simple additivity for the three bacterial
species. The Gram negative species showed only a small decrease in the
[*ARVA] required butwere still killed at close to 1 μM*ARVA in the pres-
ence of ~60 mM NaF. S. aureus exhibited a larger decrease (~3-fold) in
[*ARVA] needed down to 1.4 μM in the presence of ~70 mM NaF.
Given that many eukaryotic cells can tolerate much higher concentra-
tions of NaF [28], even the above additive improvements could bebeneﬁcial. Mai et al. [80], however, have observed synergy between
10 ppm NaF and a CAMP against the oral bacteria Streptococcus mutans.
The results for Candida are discussed below.
Results obtained for C. albicans were generally not as promising as
with the three bacterial species, but this is probably explained by the
better tolerances tometals and other toxic compounds exhibited gener-
ally by eukaryotes. In particular, eukaryotic organisms have a greater
variety of ion pumps, chaperonins, and other metal binding proteins
such as the metallothioneins [28,37]. As observed with results for the
bacterial species, however, simply relying on FICC alone and the accom-
panying interpretation may mask important information. With both
CuCl2 and ZnCl2 (Tables 1 and S2), for example, we observed a 3-fold
improvement (FICA ~ 0.33) in the [*ARVA] required for sterilization of
C. albicans. This resulted in MSC values in the 600–700 nM range for
*ARVA in the presence of 3–4 mMmetal ions.
Surprisingly, the results obtained with *ARVA:EDTA for C. albicans
(Table S4) while characterized as simple additivity were actually as
good or better than the synergism observed for the two Gram negative
species. All three were able to sterilize at concentrations of *ARVA of
~250 nM but 1 mM EDTA was required for this effect for the two
Gram negative organisms while with Candida this result required only
274 μM EDTA. In addition, Wei et al. [23] have observed synergy be-
tweenMUC7, derived from saliva, and EDTA against a pathogenic strain
of C. albicans. The only treatment that did not result in synergy or addi-
tivitywas the combination of *ARVA:NaF against Candida. In fact, we ob-
served indifference or borderline antagonism between these two
reagents. This effect is most likely due to ionic strength as the greater
tolerance for NaF exhibited by C. albicans results in N200 mM NaF
being present in the assay. High concentrations of salts are well
known to impair function of CAMPs by screening the cationic peptides
from the anionic components of the target molecules on the microbial
surface.
In this study, we analyzed, in detail, the fractional inhibitory concen-
trations of both partners in the synergy assays. By doing so,we hoped to
highlight the potential cost savings that can result for *ARVA or other
peptide drugs even in cases of simple additivity. The use of low concen-
trations of relatively inexpensive sources of toxic ions such as simple
salts like ZnCl2 or CuCl2, NaF, or Na2EDTA could help to lower the
costs for CAMP drugs. An additional advantage is that these ions are al-
ready approved and used in many other applications in food, agricul-
ture, and medicine. Our results on the additive and synergistic effects
of toxic ions when used in combination with the CAMP *ARVA may
have important clinical implications for the development of future
treatments and formulations involving antimicrobial peptides.
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